LitAlert ~~ GeneLit.com

    • A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
    • Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q.
    • J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
    • Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    • Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.
    • Gynecol Oncol. 2020 Sep 18:S0090-8258(20)33814-2. doi: 10.1016/j.ygyno.2020.08.013. Epub ahead of print.
    • Robot-assisted Nipple-sparing Mastectomy with Immediate Breast Reconstruction: An Initial Experience of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).
    • Ryu JM, Kim JY, Choi HJ, Ko BS, Kim J, Cho J, Lee MH, Choi JE, Kim JH, Lee J, Jung SM, Shin HJ, Lee J, Park HS.
    • Ann Surg. 2020 Sep 15. doi: 10.1097/SLA.0000000000004492. Epub ahead of print.
    • Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    • Hilmi M, Neuzillet C.
    • Bull Cancer. 2020 Sep 14:S0007-4551(20)30324-6. French. doi: 10.1016/j.bulcan.2020.06.009. Epub ahead of print.
    • Letter, News, [Article in French]
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.